HDAC Inhibitor Market in the United States is benefiting from the availability of approved HDAC inhibitor therapies for certain hematological malignancies. These established treatment options support clinical experience while encouraging research into additional compounds and therapeutic applications. The HDAC Inhibitor Market was valued at US$ 1.42 billion in 2025 and is projected to reach US$...